63,198 research outputs found

    CGIAR Excellence in Breeding Platform - Plan of Work and Budget 2020

    Get PDF
    At the end of 2019, all CGIAR centers had submitted improvement plans based on an EiB template and in close collaboration with EiB staff while – in a parallel process with breeding programs, funders and private sector representatives – a vision for breeding program modernization was developed and presented to CGIAR breeding leadership at the EiB Annual Meeting. This vision represents an evolution of EiB in the context of the Crops to End Hunger Initiative (CtEH) beyond the initial scope of providing tools, services and expert advice, and serves as a guide for Center leadership to drive changes with EiB support. In addition, EiB has taken the role of managing and disbursing funding, made available by Funders via CtEH to modernize breeding and enable CGIAR breeding programs to implement the vision provided by EiB

    Accelerating Change for Women and Girls: The Role of Women's Funds

    Get PDF
    In recent years, interest in philanthropy for and by women has intensified, accompanied by a growing acceptance of the idea that philanthropic investments in women and girls can accelerate positive change in communities. To understand this evolution in thinking and practice within philanthropy, the Foundation Center partnered with the Women's Funding Network, a global movement of women's funds, to chart the current landscape of philanthropy focused on women and girls and document the specific role played by women's funds

    The Price of Progress: Funding and Financing Alzheimer\u27s Disease Drug Development

    Get PDF
    Introduction Advancing research and treatment for Alzheimer\u27s disease (AD) and the search for effective treatments depend on a complex financial ecosystem involving federal, state, industry, advocacy, venture capital, and philanthropy funding approaches. Methods We conducted an expert review of the literature pertaining to funding and financing of translational research and drug development for AD. Results The federal government is the largest public funder of research in AD. The National Institute on Aging, National Institute of Mental Health, National Institute of General Medical Sciences, and National Center for Advancing Translational Science all fund aspects of research in AD drug development. Non-National Institutes of Health federal funding comes from the National Science Foundation, Veterans Administration, Food and Drug Administration, and the Center for Medicare and Medicaid Services. Academic Medical Centers host much of the federally funded basic science research and are increasingly involved in drug development. Funding of the “Valley of Death” involves philanthropy and federal funding through small business programs and private equity from seed capital, angel investors, and venture capital companies. Advocacy groups fund both basic science and clinical trials. The Alzheimer Association is the advocacy organization with the largest research support portfolio relevant to AD drug development. Pharmaceutical companies are the largest supporters of biomedical research worldwide; companies are most interested in late stage de-risked drugs. Drugs progressing into phase II and III are candidates for pharmaceutical industry support through licensing, mergers and acquisitions, and co-development collaborations. Discussion Together, the funding and financing entities involved in supporting AD drug development comprise a complex, interactive, dynamic financial ecosystem. Funding source interaction is largely unstructured and available funding is insufficient to meet all demands for new therapies. Novel approaches to funding such as mega-funds have been proposed and more integration of component parts would assist in accelerating drug development

    Committed to Safety: Ten Case Studies on Reducing Harm to Patients

    Get PDF
    Presents case studies of healthcare organizations, clinical teams, and learning collaborations to illustrate successful innovations for improving patient safety nationwide. Includes actions taken, results achieved, lessons learned, and recommendations

    Applying Gender Action Plan Lessons: A Three-Year Road Map for Gender Mainstreaming (2011- 2013)

    Get PDF
    This transition plan identifies key lessons from the implementation of the World Bank Group action plan, Gender Equality as Smart Economics (GAP), and sets out a proposal to improve the performance on Gender and Development. It seeks to strengthen the implementation of the Bank?s gender policy and places special emphasis on improving attention to gender in Bank instruments (CASs). It covers World Bank Group (WBG) operations from 2011 to 2013, and was produced on a request by the World Bank Board of Executive Directors. A GAP Three-year Progress Report accompanies this plan

    Influence network linkages across implementation strategy conditions in a randomized controlled trial of two strategies for scaling up evidence-based practices in public youth-serving systems.

    Get PDF
    BackgroundGiven the importance of influence networks in the implementation of evidence-based practices and interventions, it is unclear whether such networks continue to operate as sources of information and advice when they are segmented and disrupted by randomization to different implementation strategy conditions. The present study examines the linkages across implementation strategy conditions of social influence networks of leaders of youth-serving systems in 12 California counties participating in a randomized controlled trial of community development teams (CDTs) to scale up use of an evidence-based practice.MethodsSemi-structured interviews were conducted with 38 directors, assistant directors, and program managers of county probation, mental health, and child welfare departments. A web-based survey collected additional quantitative data on information and advice networks of study participants. A mixed-methods approach to data analysis was used to create a sociometric data set (n = 176) to examine linkages between treatment and standard conditions.ResultsOf those network members who were affiliated with a county (n = 137), only 6 (4.4%) were directly connected to a member of the opposite implementation strategy condition; 19 (13.9%) were connected by two steps or fewer to a member of the opposite implementation strategy condition; 64 (46.7%) were connected by three or fewer steps to a member of the opposite implementation strategy condition. Most of the indirect steps between individuals who were in different implementation strategy conditions were connections involving a third non-county organizational entity that had an important role in the trial in keeping the implementation strategy conditions separate. When these entities were excluded, the CDT network exhibited fewer components and significantly higher betweenness centralization than did the standard condition network.ConclusionAlthough the integrity of the RCT in this instance was not compromised by study participant influence networks, RCT designs should consider how influence networks may extend beyond boundaries established by the randomization process in implementation studies.Trial registrationNCT00880126
    • …
    corecore